Skip to main content

Table 4 Results of this analysis with a large population size

From: Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Cardiovascular outcomes assessed No of studies involved (n) OR with 95% CI P value I2 value (%)
Primary endpoint 6 0.95 [0.86–1.04] 0.26 65
Cardiovascular death 5 1.00 [0.90–1.10] 0.93 31
All-cause mortality 6 0.84 [0.59–1.18] 0.31 97
Stroke 5 1.03 [0.89–1.18] 0.72 0
Myocardial infarction 5 0.97 [0.88–1.07] 0.59 0
Hospitalization for cardiovascular complications 4 1.02 [0.96–1.09] 0.45 0
Hospitalization specifically for heart failure 4 1.05 [0.90–1.23] 0.55 64
  1. Abbreviations: OR Odds ratios, CI Confidence intervals